Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Status:
Withdrawn
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Regorafenib has been proved to improved survival in patients with metastatic colorectal
cancer who have been failed to all of known standard chemotherapy (The CORRECT study). The
phase Ib study of regorafenib plus FOLFOX or FOLFIRI was performed and the dose of
regorafenib was fixed; 160 mg/day on days 4 to 10 (7 days per cycle when combined with FOLFOX
or FOLFIRI). Regorafenib plus FOLFOX as second-line chemotherapy in mCRC patients who
progressed after first-line irinotecan-based chemotherapy has not been studied yet, and
because there have been unmet needs for the discovery of valid targeted agent combination for
the second-line FOLFOX as above reasons, the investigators planned this study of regorafenib
plus FOLFOX as second-line chemotherapy in mCRC patients who progressed after first-line
irinotecan-based chemotherapy.